IRVINE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences. The first presentation will be at the Canaccord Adams 3rd Annual Cardiovascular Conference at the Nikko Hotel in San Francisco, CA.
Event: Canaccord Adams 3rd Annual Cardiovascular Conference Date: Tuesday, November 10, 2009 Time: 11:00 a.m. PT
The second presentation will be at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City.
Event: Lazard Capital Markets 6th Annual Healthcare Conference Date: Wednesday, November 18, 2009 Time: 10:00 a.m. ET
The third presentation will be at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City.
Event: Piper Jaffray 21st Annual Health Care Conference Date: Tuesday, December 1, 2009 Time: 2:30 p.m. ET
An audio Web cast of the Company's presentations will be available by visiting the investor relations section of Endologix's Web site at www.endologix.com. A replay of the presentations will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com
COMPANY CONTACT: INVESTOR CONTACTS: ---------------- ------------------ Endologix, Inc. The Ruth Group John McDermott, CEO Nick Laudico (646) 536-7030 (949) 595-7200 Zack Kubow (646) 536-7020 www.endologix.com
SOURCE Endologix, Inc.
|SOURCE Endologix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved